Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below 50 Day Moving Average – Time to Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s stock price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $8.31 and traded as low as $7.53. Seres Therapeutics shares last traded at $7.63, with a volume of 25,619 shares traded.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on MCRB shares. Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Canaccord Genuity Group reiterated a “buy” rating and set a $22.00 target price on shares of Seres Therapeutics in a research note on Friday, March 13th. Finally, Wall Street Zen lowered shares of Seres Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Seres Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $22.00.

Seres Therapeutics Stock Up 0.5%

The firm’s 50 day simple moving average is $8.31 and its two-hundred day simple moving average is $12.20. The stock has a market cap of $73.86 million, a P/E ratio of -1.48 and a beta of 0.12.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The firm had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.36 million.

Hedge Funds Weigh In On Seres Therapeutics

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Seres Therapeutics by 6.8% during the third quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after acquiring an additional 19,793 shares during the last quarter. Invesco Ltd. grew its position in shares of Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 89,995 shares during the last quarter. Vontobel Holding Ltd. grew its position in shares of Seres Therapeutics by 4.8% during the fourth quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock worth $1,536,000 after acquiring an additional 4,723 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Seres Therapeutics during the second quarter worth about $1,016,000. Finally, Geode Capital Management LLC grew its position in shares of Seres Therapeutics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after acquiring an additional 1,160 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.